Strong Clinical Efficacy and Tolerability Profile: Their lead candidates, LNZ100 and LNZ101, have demonstrated rapid onset, sustained duration, and good tolerability in pivotal Phase 3 trials, positioning them as potentially best-in-class treatments for presbyopia.

Large and Underserved Market Opportunity: Presbyopia is a prevalent age-related condition affecting a significant global population, representing a substantial market with high unmet needs for effective, long-lasting solutions.

Differentiated Combination Therapy Approach: Lenz Therapeutics employs a unique combination of miotic agents (acetonapthone and pilocarpine) designed to optimize pupil constriction for visual acuity while minimizing common side effects associated with single-agent therapies.